Multiple Benefits of a Point-of-Care Immunoassay Analyzer in Diverse Applications and Environments

Tuesday, August 6, 12:30 – 12:50 p.m.
Exhibit Hall, Theater 3
Supported by Sanwa Biotech Ltd.


Sanwa Biotech Ltd. is developing innovative microfluidic diagnostic systems for point-of-care and laboratory applications in different fields, using the company’s proprietary platform, ALiA. The mobile device allows accurate diagnosis of multiple biomarkers within 15 minutes in liquid samples without any sample preparation. It can be used in a laboratory, in a physician office, or in a remote area. In this session, Dr. Isabelle Dutry, CSO of Sanwa Biotech Ltd., will introduce the multiple potential applications of ALiA, how this platform can be implemented in diverse environments, and how it can improve the management of life-threatening diseases in a timely manner.


After attending this session, participants will be able to:

  • Understand technology principles of the fully integrated microfluidic POC platform and how it allows simultaneous diagnosis of different biomarkers.
  • Appreciate the benefits of rapid, accurate, and comprehensive multiplexed diagnostic tests in different environments.
  • Understand the positive impact of POCT on clinical and economic outcomes.


Isabelle Dutry
Chief Scientist Officer
Sanwa Biotech Ltd.
Hong Kong, Hong Kong SAR